Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 8/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12410860 | 0.83 | GAA (0.56) | KDM4EGAAPIK3CGBTKFABP4 | |
| SCHEMBL12321703 | 0.81 | PIK3CG (0.41) | KDM4EGAAPIK3CGBTKFABP4 | |
| SCHEMBL17645642 | 0.81 | PIK3CG (0.41) | KDM4EGAAPIK3CGBTKFABP4 | |
| SCHEMBL12410863 | 0.81 | PIK3CG (0.41) | KDM4EGAAPIK3CGBTKFABP4 | |
| SCHEMBL15221457 | 0.80 | PIK3CG (0.39) | KDM4EGAAPIK3CGBTKFABP4 | |
| SCHEMBL8005374 | 0.77 | IRAK4 (0.37) | KDM4EGAASCN10A | |
| SCHEMBL12410858 | 0.77 | PIK3CG (0.40) | KDM4EGAAPIK3CG | |
| SCHEMBL17664609 | 0.77 | GAA (0.40) | KDM4EGAAPIK3CGBTKLCK | |
| Hydrochloric Acid SCHEMBL30484796 | 0.75 | PIK3CG (0.39) | KDM4EGAAPIK3CG | |
| SCHEMBL7271827 | 0.74 | PIK3CG (0.44) | KDM4EGAAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | KDM4E 3088/4885GAA 218/4885PIK3CG 1174/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | KDM4E 3088/4885GAA 218/4885PIK3CG 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.